Related Experiment Video
Updated: Dec 17, 2025

Comparing the Affinity of GTPase-binding Proteins using Competition Assays
Published on: October 8, 2015
A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not
Alexia Hervieu1,2, Sara Farrah Heuss1, Chi Zhang2
1Spatial Signalling Team, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.
Abstract:
Receptor tyrosine kinases (RTKs) are often overexpressed or mutated in cancers and drive tumor growth and metastasis. In the current model of RTK signaling, including that of MET, downstream phosphatidylinositol 3-kinase (PI3K) mediates both cell proliferation and cell migration, whereas the small guanosine triphosphatase (GTPase) Rac1 mediates cell migration. However, in cultured NIH3T3 and glioblastoma cells, we found that class I PI3K mediated oncogenic MET-induced cell migration but not anchorage-independent growth. In contrast, Rac1 regulated both processes in distinct ways. Downstream of PI3K, Rac1 mediated cell migration through its GTPase activity, whereas independently of PI3K, Rac1 mediated anchorage-independent growth in a GTPase-independent manner through an adaptor function. Through its RKR motif, Rac1 formed a complex with the kinase mTOR to promote its translocation to the plasma membrane, where its activity promoted anchorage-independent growth of the cell cultures. Inhibiting mTOR with rapamycin suppressed the growth of subcutaneous MET-mutant cell grafts in mice, including that of MET inhibitor-resistant cells. These findings reveal a GTPase-independent role for Rac1 in mediating a PI3K-independent MET-to-mTOR pathway and suggest alternative or combined strategies that might overcome resistance to RTK inhibitors in patients with cancer.
Insights
Receptor tyrosine kinases (RTKs) drive cancer. This study reveals Rac1
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Receptor tyrosine kinases (RTKs) like MET are crucial in cancer development and progression.
- Current models implicate phosphatidylinositol 3-kinase (PI3K) and Rac1 in RTK signaling pathways.
- Understanding these pathways is key to developing effective cancer therapies.
Purpose of the Study:
- To elucidate the distinct roles of PI3K and Rac1 in MET-driven cancer.
- To investigate novel signaling pathways involved in anchorage-independent growth.
- To identify potential therapeutic targets for overcoming resistance to RTK inhibitors.
Main Methods:
- Utilized cultured NIH3T3 and glioblastoma cells to study MET signaling.
- Investigated Rac1's GTPase-dependent and -independent functions.
- Examined the interaction between Rac1, mTOR, and cellular processes.
- Assessed the efficacy of mTOR inhibition using rapamycin in mouse models.
Main Results:
- Class I PI3K mediated MET-induced cell migration but not anchorage-independent growth.
- Rac1 regulated cell migration via GTPase activity and anchorage-independent growth independently of PI3K.
- Rac1's adaptor function, through its RKR motif, facilitated mTOR translocation and promoted anchorage-independent growth.
- mTOR inhibition with rapamycin suppressed tumor growth in MET-mutant and resistant cell grafts.
Conclusions:
- Discovered a PI3K-independent MET-to-mTOR pathway mediated by Rac1's GTPase-independent function.
- Rac1 plays a dual role in MET signaling, affecting both migration and anchorage-independent growth.
- Targeting the Rac1-mTOR pathway offers a potential strategy to overcome resistance to RTK inhibitors in cancer treatment.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mechanism of Lamellipodia Formation
Cell Polarization by Rho Proteins
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Intracellular Signaling Affects Focal Adhesions
Some...

